Target intelligence / Profile preview

Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13)

Target
HSD17B13
Molecular classification
Enzyme, Oxidoreductase, Dehydrogenase
01

Overview

Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) is a liver-enriched, hepatocyte-specific enzyme that localizes to the surface of lipid droplets. It belongs to the 17-beta-hydroxysteroid dehydrogenase family and is involved in the metabolism of lipids, steroids, and retinoids. Although its exact physiological substrates and molecular mechanisms remain incompletely understood, it is known to play a key role in hepatic lipid droplet biogenesis and lipid accumulation.

Human genetic studies have strongly validated HSD17B13 as a therapeutic target, showing that loss-of-function variants (such as rs72613567) provide significant protection against the progression of chronic liver diseases. This genetic protection spans metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease, cirrhosis, and hepatocellular carcinoma. Consequently, therapeutic strategies targeting HSD17B13 are under active clinical development to treat fibrotic liver diseases. These approaches include RNA interference (RNAi) therapeutics like rapirosiran and ARO-HSD, as well as oral small-molecule inhibitors like INI-822.

Other names
17-beta-hydroxysteroid dehydrogenase 1317-beta-HSD 13SCDR9SDR16C3Short-chain dehydrogenase/reductase 9Short chain dehydrogenase/reductase family 16C member 3Hepatic retinol/retinal dehydrogenase
02

Mechanism of action

RNA interference (gene silencing) and small-molecule enzymatic inhibition

03

Biological functions

Lipid metabolismSteroid metabolismRetinoid metabolismLipid droplet organization
04

Disease associations

Metabolic dysfunction-associated steatohepatitisNon-alcoholic fatty liver diseaseLiver fibrosisCirrhosisAlcoholic liver diseaseHepatocellular carcinoma
05

Safety considerations

Injection-site reactionsPotential off-target effects of RNAiLong-term safety of sustained gene silencingIncomplete understanding of physiological substrates
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Alanine aminotransferaseAspartate aminotransferaseHSD17B13 mRNA expressionHSD17B13 genotype (rs72613567)NAFLD activity score

Beyond the preview

Go deeper on Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call